Muhammad Adil Sheikh1, Xiaowen Kong2, Brian Haymart2, Scott Kaatz3, Gregory Krol3, Jay Kozlowski4, Musa Dahu5, Mona Ali6, Steven Almany6, Tina Alexandris-Souphis2, Eva Kline-Rogers2, James B Froehlich2, Geoffrey D Barnes7. 1. Division of Hospital Medicine, University of Michigan, Ann Arbor, MI, United States of America. 2. Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, United States of America. 3. Henry Ford Hospital, Detroit, MI, United States of America. 4. Cardiology and Vascular Associates, Huron Valley-Sinai Hospital, Commerce Township, MI, United States of America. 5. Spectrum Health System, Grand Rapids, MI, United States of America. 6. Beaumont Hospital, Royal Oak, MI, United States of America. 7. Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, United States of America. Electronic address: gbarnes@med.umich.edu.
Abstract
INTRODUCTION: Limited data is available on the rates of bleeding and thromboembolic events for patients undergoing low bleeding risk procedures while taking direct oral anticoagulants (DOAC). METHODS: Adults taking DOAC in the Michigan Anticoagulation Quality Improvement Initiative (MAQI2) database who underwent a low bleeding risk procedure between May 2015 and Sep 2019 were included. Thirty-day bleeding (of any severity), thromboembolic events, and death were compared between DOAC temporarily interrupted and continued uninterrupted groups. Adverse event rates were compared using an inverse probability weighting propensity score. RESULTS: There were 820 patients who underwent 1412 low risk procedures. DOAC therapy was temporarily interrupted in 371 (45.2%) patients (601 [42.6%] procedures) and continued uninterrupted in 449 (54.8%) patients (811 [57.4%] procedures). DOAC patients with temporary interruptions were more likely to have diabetes, prior stroke or TIA, prior bleeding, higher CHA2DS2-VASc, and higher modified HAS-BLED scores. DOAC interruption was common for gastrointestinal endoscopy, electrophysiology device implantation, and cardiac catheterization while it was less common for cardioversion, dermatologic procedures, and subcutaneous injection. After propensity score adjustment, bleeding risk was lower in the DOAC temporary interruption group (OR 0.62, 95% CI 0.41-0.95) as compared to the group with continuous DOAC use. Rates of thromboembolic events and death did not differ significantly between the two groups. CONCLUSIONS: DOAC-treated patients undergoing low bleeding risk procedures may experience lower rates of bleeding when DOAC is temporarily interrupted. Prospective studies focused on low bleeding risk procedures are needed to identify the safety DOAC management strategy.
INTRODUCTION: Limited data is available on the rates of bleeding and thromboembolic events for patients undergoing low bleeding risk procedures while taking direct oral anticoagulants (DOAC). METHODS: Adults taking DOAC in the Michigan Anticoagulation Quality Improvement Initiative (MAQI2) database who underwent a low bleeding risk procedure between May 2015 and Sep 2019 were included. Thirty-day bleeding (of any severity), thromboembolic events, and death were compared between DOAC temporarily interrupted and continued uninterrupted groups. Adverse event rates were compared using an inverse probability weighting propensity score. RESULTS: There were 820 patients who underwent 1412 low risk procedures. DOAC therapy was temporarily interrupted in 371 (45.2%) patients (601 [42.6%] procedures) and continued uninterrupted in 449 (54.8%) patients (811 [57.4%] procedures). DOAC patients with temporary interruptions were more likely to have diabetes, prior stroke or TIA, prior bleeding, higher CHA2DS2-VASc, and higher modified HAS-BLED scores. DOAC interruption was common for gastrointestinal endoscopy, electrophysiology device implantation, and cardiac catheterization while it was less common for cardioversion, dermatologic procedures, and subcutaneous injection. After propensity score adjustment, bleeding risk was lower in the DOAC temporary interruption group (OR 0.62, 95% CI 0.41-0.95) as compared to the group with continuous DOAC use. Rates of thromboembolic events and death did not differ significantly between the two groups. CONCLUSIONS: DOAC-treated patients undergoing low bleeding risk procedures may experience lower rates of bleeding when DOAC is temporarily interrupted. Prospective studies focused on low bleeding risk procedures are needed to identify the safety DOAC management strategy.
Authors: Hugh Calkins; Stephan Willems; Edward P Gerstenfeld; Atul Verma; Richard Schilling; Stefan H Hohnloser; Ken Okumura; Harvey Serota; Matias Nordaby; Kelly Guiver; Branislav Biss; Marc A Brouwer; Massimo Grimaldi Journal: N Engl J Med Date: 2017-03-19 Impact factor: 91.245
Authors: David H Birnie; Jeff S Healey; George A Wells; Atul Verma; Anthony S Tang; Andrew D Krahn; Christopher S Simpson; Felix Ayala-Paredes; Benoit Coutu; Tiago L L Leiria; Vidal Essebag Journal: N Engl J Med Date: 2013-05-09 Impact factor: 91.245
Authors: Andrew B Hughey; Xiaokui Gu; Brian Haymart; Eva Kline-Rogers; Steve Almany; Jay Kozlowski; Dennis Besley; Gregory D Krol; Syed Ahsan; Scott Kaatz; James B Froehlich; Geoffrey D Barnes Journal: J Thromb Thrombolysis Date: 2018-10 Impact factor: 2.300
Authors: James D Douketis; Alex C Spyropoulos; Scott Kaatz; Richard C Becker; Joseph A Caprini; Andrew S Dunn; David A Garcia; Alan Jacobson; Amir K Jaffer; David F Kong; Sam Schulman; Alexander G G Turpie; Vic Hasselblad; Thomas L Ortel Journal: N Engl J Med Date: 2015-06-22 Impact factor: 91.245
Authors: Geoffrey D Barnes; Scott Kaatz; Vlad Golgotiu; Xiaokui Gu; Adam Leidal; Abdallah Kobeissy; Brian Haymart; Eva Kline-Rogers; Jay Kozlowski; Steve Almany; Tom Leyden; James B Froehlich Journal: J Thromb Thrombolysis Date: 2013-01 Impact factor: 2.300
Authors: James D Douketis; Alex C Spyropoulos; Joanne Duncan; Marc Carrier; Gregoire Le Gal; Alfonso J Tafur; Thomas Vanassche; Peter Verhamme; Sudeep Shivakumar; Peter L Gross; Agnes Y Y Lee; Erik Yeo; Susan Solymoss; Jeannine Kassis; Geneviève Le Templier; Stephen Kowalski; Mark Blostein; Vinay Shah; Elizabeth MacKay; Cynthia Wu; Nathan P Clark; Shannon M Bates; Frederick A Spencer; Eleni Arnaoutoglou; Michiel Coppens; Donald M Arnold; Joseph A Caprini; Na Li; Karen A Moffat; Summer Syed; Sam Schulman Journal: JAMA Intern Med Date: 2019-11-01 Impact factor: 21.873